Stock ELDN ELEDON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
2.58 USD -8.51% Intraday chart for Eledon Pharmaceuticals, Inc. -16.50% +43.33%
May. 09 Eledon Pharmaceuticals, Inc. announced that it has received $49.99901 million in funding CI
May. 07 Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
GL
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
GL
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
GL
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
GL
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
GL
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
GL
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
GL
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
AQ
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
GL
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
GL
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
GL
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GL
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
GL
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
AQ
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELDN Stock
  4. News Eledon Pharmaceuticals, Inc.
  5. Press Releases